{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:15:25Z","timestamp":1794809725892,"version":"4.9.1"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth leading cause of cancer-related death worldwide. HCC often occurs in the setting of chronic liver disease or cirrhosis. Recent evidence has highlighted the importance of the immune microenvironment in the development and progression of HCC, as well as its role in the potential response to therapy. Liver disease such as viral hepatitis, alcohol induced liver disease, and non-alcoholic fatty liver disease is a major risk factor for the development of HCC and has been demonstrated to alter the immune microenvironment. Alterations in the immune microenvironment may markedly influence the response to different therapeutic strategies. As such, research has focused on understanding the complex relationship among tumor cells, immune cells, and the surrounding liver parenchyma to treat HCC more effectively. We herein review the immune microenvironment, as well as the relative effect of liver disease on the immune microenvironment. In addition, we review how changes in the immune microenvironment can lead to therapeutic resistance, as well as highlight future strategies aimed at developing the next-generation of therapies for HCC.<\/jats:p>","DOI":"10.3389\/fphar.2023.1225821","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T18:16:47Z","timestamp":1691432207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The effect of liver disease on hepatic microenvironment and implications for immune therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Zachary J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/evidoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"B2","volume-title":"Cellular and molecular immunology","author":"Abul","year":"2007"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 annual report of the European liver transplant registry (ELTR) - 50-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl. Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bbadis.2017.11.026","article-title":"Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment","volume":"1864","author":"Agosti","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/liv.14226","article-title":"Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy","volume":"40","author":"Amaddeo","year":"2020","journal-title":"Liver Int. official J. Int. Assoc. Study Liver"},{"key":"B7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/hep4.1146","article-title":"Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease","volume":"2","author":"Amer","year":"2018","journal-title":"Hepatol. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J. hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1158\/1078-0432.CCR-20-1497","article-title":"Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma","volume":"26","author":"Bassaganyas","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.immuni.2021.08.006","article-title":"A subset of Kupffer cells regulates metabolism through the expression of CD36","volume":"54","author":"Bl\u00e9riot","year":"2021","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"166S-71S","DOI":"10.1097\/01.alc.0000189280.19073.28","article-title":"Activation of the innate immune system and alcoholic liver disease: Effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol?","volume":"29","author":"Bode","year":"2005","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.3390\/cancers13174387","article-title":"Role of virus-related chronic inflammation and mechanisms of cancer immune-suppression in pathogenesis and progression of hepatocellular carcinoma","volume":"13","author":"Borgia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.3390\/ijms23158112","article-title":"Chemokine CXCL10 modulates the tumor microenvironment of fibrosis-associated hepatocellular carcinoma","volume":"23","author":"Brandt","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.alcohol.2005.03.009","article-title":"DNA adducts from acetaldehyde: Implications for alcohol-related carcinogenesis","volume":"35","author":"Brooks","year":"2005","journal-title":"AlcoholFayettev. NY)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41419-018-0687-6","article-title":"Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4(+) T cell apoptosis promoting HCC development","volume":"9","author":"Brown","year":"2018","journal-title":"Cell Death Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/hep.30633","article-title":"Adjuvant treatment of hepatocellular carcinoma: Prospect of immunotherapy","volume":"70","author":"Brown","year":"2019","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: A review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/cam4.4906","article-title":"Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"12","author":"Chapin","year":"2023","journal-title":"Cancer Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.toxlet.2015.11.019","article-title":"Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding","volume":"241","author":"Chen","year":"2016","journal-title":"Toxicol. Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","article-title":"Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: A multicenter retrospective study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"D'Souza","year":"2020","journal-title":"World J. gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2147\/JHC.S325959","article-title":"Molecular signature and immune landscape of HCV-associated hepatocellular carcinoma (HCC): Differences and similarities with HBV-HCC","volume":"8","author":"De Battista","year":"2021","journal-title":"J. Hepatocell. carcinoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.3390\/cancers14194616","article-title":"Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"14","author":"De Lorenzo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"733530","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral status and efficacy of immunotherapy in hepatocellular carcinoma: A systematic review with meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/jco.2021.39.15_suppl.4071","article-title":"IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor)","volume":"39","author":"Ducreux","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00535-019-01620-7","article-title":"Microsatellite instability and immune checkpoint inhibitors: Toward precision medicine against gastrointestinal and hepatobiliary cancers","volume":"55","author":"Eso","year":"2020","journal-title":"J. gastroenterology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7150\/jca.2.123","article-title":"In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice","volume":"2","author":"Feng","year":"2011","journal-title":"J. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet (London, Engl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/gutjnl-2015-310814","article-title":"Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma","volume":"66","author":"Garnelo","year":"2017","journal-title":"Gut"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1371\/journal.pbio.0030113","article-title":"Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids","volume":"3","author":"Geissmann","year":"2005","journal-title":"PLoS Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"eaai7616","DOI":"10.1126\/sciimmunol.aai7616","article-title":"Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome","volume":"2","author":"Ghazarian","year":"2017","journal-title":"Sci. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.21147\/j.issn.1000-9604.2023.02.02","article-title":"When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road","volume":"35","author":"Gu","year":"2023","journal-title":"Chin. J. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12865-017-0215-y","article-title":"The imbalance of Th17\/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice","volume":"18","author":"He","year":"2017","journal-title":"BMC Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","article-title":"Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice","volume":"160","author":"Heinrich","year":"2021","journal-title":"Gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cam4.4854","article-title":"Does first-line treatment have prognostic impact for unresectable HCC?","volume":"12","author":"Hiraoka","year":"2023","journal-title":"Cancer Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"760860","DOI":"10.3389\/fendo.2021.760860","article-title":"Emerging roles of T cells in the pathogenesis of nonalcoholic steatohepatitis and hepatocellular carcinoma","volume":"12","author":"Hirsova","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1189\/jlb.0308173","article-title":"Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury","volume":"84","author":"Holt","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/ol.2019.10293","article-title":"Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in non-small-cell lung cancer","volume":"18","author":"Ichinokawa","year":"2019","journal-title":"Oncol. Lett."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-17-0289","article-title":"Immunotherapy of hepatocellular carcinoma: Facts and hopes","volume":"24","author":"Inarrairaegui","year":"2017","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/MCG.0000000000000161","article-title":"Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States","volume":"49","author":"Jinjuvadia","year":"2015","journal-title":"J. Clin. gastroenterology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/apt.17441","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort","volume":"57","author":"Jost-Brinkmann","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/hep.23253","article-title":"Major histocompatibility complex class I-related chains A and B (MIC A\/B): A novel role in nonalcoholic steatohepatitis","volume":"51","author":"Kahraman","year":"2010","journal-title":"Hepatology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1002\/hep.31210","article-title":"Liver transplantation outcomes in a U.S. Multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria","volume":"72","author":"Kardashian","year":"2020","journal-title":"Hepatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"lancet Gastroenterology hepatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2021.05.007","article-title":"Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation","volume":"513","author":"Ke","year":"2021","journal-title":"Cancer Lett."},{"key":"B61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","article-title":"Tremelimumab: First approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3390\/cancers14071747","article-title":"Atezolizumab\/bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: A real-world, multi-center study","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s12276-020-0480-3","article-title":"Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma","volume":"52","author":"Koo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and child-pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J. Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jhep.2013.02.032","article-title":"NKT-Cell subsets: Promoters and protectors in inflammatory liver disease","volume":"59","author":"Kumar","year":"2013","journal-title":"J. Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.transproceed.2023.03.064","article-title":"Optimizing the safe washout period for liver transplantation following immune checkpoint inhibitors with atezolizumab, nivolumab, or pembrolizumab","volume":"55","author":"Kuo","year":"2023","journal-title":"Transpl. Proc."},{"key":"B68","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Sci. (New York, NY)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"454","DOI":"10.21873\/invivo.13099","article-title":"Bevacizumab and atezolizumab for unresectable hepatocellular carcinoma: Real-world data in taiwan-tainan medical oncology group H01 trial","volume":"37","author":"Lee","year":"2023","journal-title":"Vivo"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"B72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cdtm.2016.09.001","article-title":"Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression","volume":"2","author":"Li","year":"2016","journal-title":"Chronic Dis. Transl. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"B74","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: Key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet (London, Engl."},{"key":"B76","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B77","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.freeradbiomed.2007.11.004","article-title":"CYP2E1 and oxidative liver injury by alcohol","volume":"44","author":"Lu","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations","volume":"9","author":"MacParland","year":"2018","journal-title":"Nat. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","article-title":"The yin and yang of evasion and immune activation in HCC","volume":"62","author":"Makarova-Rusher","year":"2015","journal-title":"J. hepatology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/01.RVI.0000161377.33557.20","article-title":"Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm","volume":"16","author":"Maluccio","year":"2005","journal-title":"J. Vasc. Interv. Radiol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jvir.2008.02.013","article-title":"Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma","volume":"19","author":"Maluccio","year":"2008","journal-title":"J. Vasc. Interv. Radiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1055\/s-0029-1214377","article-title":"Role of alcohol in liver carcinogenesis","volume":"29","author":"McKillop","year":"2009","journal-title":"Seminars liver Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2131\/jts.32.453","article-title":"Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis","volume":"32","author":"Nagata","year":"2007","journal-title":"J. Toxicol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fimmu.2014.00221","article-title":"Role of toll-like receptors in immune activation and tolerance in the liver","volume":"5","author":"Nakamoto","year":"2014","journal-title":"Front. Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2337\/db09-1403","article-title":"C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis","volume":"59","author":"Obstfeld","year":"2010","journal-title":"Diabetes"},{"key":"B89","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"653437","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: A cohort study and literature review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front. Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1002\/hep.21060","article-title":"The liver as an immunological organ","volume":"43","author":"Racanelli","year":"2006","journal-title":"Hepatology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","article-title":"CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation","volume":"18","author":"Rakhra","year":"2010","journal-title":"Cancer Cell"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/hep.32336","article-title":"T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis","volume":"75","author":"Ramadori","year":"2022","journal-title":"Hepatol. Baltim. Md)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"B95","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. hepatology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2353\/ajpath.2009.080999","article-title":"Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis","volume":"175","author":"Rensen","year":"2009","journal-title":"Am. J. Pathol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.21037\/jgo-22-922","article-title":"Immune checkpoint inhibitors in liver transplant: A case series","volume":"14","author":"Rudolph","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/ajt.16965","article-title":"Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab","volume":"22","author":"Schnickel","year":"2022","journal-title":"Am. J. Transpl."},{"key":"B101","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/jama.2020.10437","article-title":"Nonalcoholic steatohepatitis-reply","volume":"324","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"B102","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cgh.2013.06.013","article-title":"Alcoholic hepatitis: Current challenges and future directions","volume":"12","author":"Singal","year":"2014","journal-title":"Clin. gastroenterology hepatology official Clin. Pract. J. Am. Gastroenterological Assoc."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/hep.25674","article-title":"Chronic inflammation, immune escape, and oncogenesis in the liver: A unique neighborhood for novel intersections","volume":"56","author":"Stauffer","year":"2012","journal-title":"Hepatology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/hep.23337","article-title":"Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity","volume":"51","author":"Stienstra","year":"2010","journal-title":"Hepatology"},{"key":"B105","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: An emerging player in the progression of NAFLD","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/gutjnl-2011-301857","article-title":"NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease","volume":"61","author":"Syn","year":"2012","journal-title":"Gut"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/hep.23599","article-title":"Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease","volume":"51","author":"Syn","year":"2010","journal-title":"Hepatology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am. J. Transpl."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J. Hepatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14656566.2023.2229728","article-title":"Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma","author":"Takamoto","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"B111","doi-asserted-by":"publisher","first-page":"G605","DOI":"10.1152\/ajpgi.1998.275.4.G605","article-title":"II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin","volume":"275","author":"Thurman","year":"1998","journal-title":"Am. J. physiology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"van der Windt","year":"2018","journal-title":"Hepatology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fimmu.2019.00082","article-title":"The differential roles of T cells in non-alcoholic fatty liver disease and obesity","volume":"10","author":"Van Herck","year":"2019","journal-title":"Front. Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jhep.2021.07.032","article-title":"Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis","volume":"75","author":"Wang","year":"2021","journal-title":"J. Hepatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coi.2021.02.001","article-title":"Resistance mechanisms to checkpoint inhibitors","volume":"69","author":"Weiss","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"B119","doi-asserted-by":"publisher","first-page":"793343","DOI":"10.3389\/fimmu.2021.793343","article-title":"Epigenetic and immune-cell infiltration changes in the tumor microenvironment in hepatocellular carcinoma","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"229","DOI":"10.21037\/jgo.2017.03.14","article-title":"Viral hepatitis and hepatocellular carcinoma: Etiology and management","volume":"8","author":"Zamor","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3748\/wjg.v28.i27.3346","article-title":"Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy","volume":"28","author":"Zhang","year":"","journal-title":"World J. gastroenterology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1032819","DOI":"10.3389\/fimmu.2022.1032819","article-title":"Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis","volume":"13","author":"Zhang","year":"","journal-title":"Front. Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1225821\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T18:16:52Z","timestamp":1691432212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1225821\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":126,"alternative-id":["10.3389\/fphar.2023.1225821"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1225821","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"article-number":"1225821"}}